AJG vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AJG's deterministic health score is weak, with a Piotroski F-Score of 4/9 indicating marginal financial stability and no available Altman Z-Score to confirm safety from distress. Despite strong revenue growth of 20% YoY, earnings are sharply declining (-25.2% YoY, -54% EPS), and the stock trades at a steep valuation (P/E 40.0, Forward P/E 19.06) well above sector averages. Insider selling is aggressive ($17.16M in net sales), and recent earnings misses have become frequent, with 3 out of the last 4 quarters missing estimates. While the balance sheet shows moderate leverage (Debt/Equity 0.59), weak profitability trends, deteriorating earnings momentum, and bearish technicals point to significant near-term risks.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
AJG vs BRK-B: Head-to-Head Comparison
This page compares Arthur J. Gallagher & Co. (AJG) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.